Effect of Body Suspension and Tilting Exercises in Parkinson's Disease
24 de novembro de 2016 atualizado por: Pontificia Universidade Católica do Rio Grande do Sul
This study evaluates the effect of body suspension and tilting exercises (performed in Chordata apparatus) on the balance and mobility of subjects with Parkinson disease.
Half of patients will perform the exercise protocol while the other half will receive passive muscle stretching and maintain the usual routine.
Visão geral do estudo
Status
Concluído
Condições
Descrição detalhada
Body suspension and tilting exercises performed in the Chordata equipment might be an effective option to improve trunk muscles activation and to facilitate functional balance and mobility control in Parkinson's disease (PD).
To evaluate this hypothesis, subjects will be randomized into control group or intervention group.
Intervention group will receive 30-minute session of body suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks, while the control group will receive passive muscle stretching and maintained their usual routine during the same period.
Both groups will be assessed at baseline and immediately after the intervention protocol.
Finally, a follow-up evaluation will be performed 8 weeks after the protocol ending (to verify possible long-lasting effects of this exercise protocol).
Tipo de estudo
Intervencional
Inscrição (Real)
40
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil
- Serviço de Neurologia do Hospital São Lucas da PUCRS
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
65 anos a 85 anos (Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Subjects able to go to training or assessment places;
- Subjects that are agreement with the study protocol and sign the ;
- Subjects in stage I, II or III of Parkinson disease according to the Hoehn and Yahr scale.
Exclusion Criteria:
- Subjects do not keep their usual routine (apart of the research protocol);
- Subjects with physical or functional limitations that prevent the assessment test battery;
- Subjects with heart or lung diseases that prevent the exercise performance;
- Subjects with cancer;
- Subjects with major visual deficits;
- Subjects with recurrent vertigo;
- Subjects with uncontrolled systemic blood pressure.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention group
Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
|
The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises.
The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method.
During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles.
Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation.
Each session lasts 30 minutes.
Outros nomes:
|
|
Comparador Falso: Control group
Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
|
Subjects receiving submitted a global muscle stretching session twice a week for eight weeks.
During this period.
All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Timed Up and Go Test
Prazo: At 8th week (in the end of exercise protocol).
|
Measurement of the time in seconds for a person to rise from sitting from a standard arm chair, walk 3 meters, turn, walk back to the chair, and sit down.
The person wears regular footwear and customary walking aid.
|
At 8th week (in the end of exercise protocol).
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Berg Balance Test
Prazo: At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
The Berg Balance Scale (BBS) is a widely used clinical test of a person's static and dynamic balance abilities.
For functional balance tests, the BBS is generally considered to be the gold standard.
The test takes 15-20 minutes and comprises a set of 14 simple balance related tasks, ranging from standing up from a sitting position, to standing on one foot.
The degree of success in achieving each task is given a score of zero (unable) to four (independent), and the final measure is the sum of all of the scores.
|
At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
|
Functional Reach Test
Prazo: At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
The Functional Reach test can be administered while the patient is standing.
The patient is instructed to next to, but not touching, a wall and position the arm that is closer to the wall at 90 degrees of shoulder flexion with a closed fist.
The assessor records the starting position at the 3rd metacarpal head on the yardstick.
Instruct the patient to "Reach as far as you can forward without taking a step."
The location of the 3rd metacarpal is recorded in centimetre (cm).
Scores are determined by assessing the difference between the start and end position is the reach distance.
Three trials are done and the average of the last two is noted.
|
At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
|
Baropodometry (Stabilometric parameters)
Prazo: At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
In the test protocol adopted data uptake of the examination will be assessed walking on the pressure platform (dynamic measure) and stopped on the pressure platform with opened eyes (static measure).
|
At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
|
Unified Parkinson Disease Rating Scale (UPDRS)
Prazo: At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
The UPDRS is a rating tool to follow the longitudinal course of Parkinson's Disease.
It is made up of the 1) Mentation, Behavior, and Mood, 2) ADL and 3) Motor sections.
These are evaluated by interview.
Some sections require multiple grades assigned to each extremity.
A total of 199 points are possible.
199 represents the worst (total) disability), 0--no disability.
|
At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
|
Parkinson's Disease Questionnaire (PDQ-39)
Prazo: At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
The Parkinson's Disease Questionnaire (PDQ-39) is primarily used in clinical trials of therapeutics intended to benefit individuals with Parkinson's disease.
|
At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
|
Timed Up and Go Test
Prazo: At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
Measurement of the time in seconds for a person to rise from sitting from a standard arm chair, walk 3 meters, turn, walk back to the chair, and sit down.
The person wears regular footwear and customary walking aid.
The investigators will measure the "change" at different time frames.
|
At baseline, at 8th week (in the end of exercise protocol) and at 16th week (follow-up).
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hoehn and Yahr Staging of Parkinson's Disease
Prazo: This test will be performed just at baseline (to classify the subjects).
|
The Hoehn and Yahr scale is a commonly used system for describing how the symptoms of Parkinson's disease progress.
|
This test will be performed just at baseline (to classify the subjects).
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Investigadores
- Cadeira de estudo: Irênio G da Silva Filho, PhD, Pontificia Universidade Católica do Rio Grande do Sul
- Cadeira de estudo: Carlos Roberto M Rieder, PhD, Hospital de Clinicas de Porto Alegre
- Diretor de estudo: Régis G Mestriner, PhD, Pontificia Universidade Católica do Rio Grande do Sul
- Investigador principal: Charlene B de Oliveira, MSc, Pontificia Universidade Católica do Rio Grande do Sul
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de setembro de 2015
Conclusão Primária (Real)
1 de maio de 2016
Conclusão do estudo (Real)
1 de maio de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
28 de abril de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
4 de maio de 2016
Primeira postagem (Estimativa)
5 de maio de 2016
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
28 de novembro de 2016
Última atualização enviada que atendeu aos critérios de controle de qualidade
24 de novembro de 2016
Última verificação
1 de novembro de 2016
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 555
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Indeciso
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .